Intervention Protocol

L-acetylcarnitine for fragile X syndrome

  1. José-Ramón Rueda1,*,
  2. Virginia Guillén2,
  3. Javier Ballesteros2,3,
  4. Maria-Isabel Tejada4,
  5. Ivan Solà5

Editorial Group: Cochrane Developmental, Psychosocial and Learning Problems Group

Published Online: 15 AUG 2012

DOI: 10.1002/14651858.CD010012


How to Cite

Rueda JR, Guillén V, Ballesteros J, Tejada MI, Solà I. L-acetylcarnitine for fragile X syndrome (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 8. Art. No.: CD010012. DOI: 10.1002/14651858.CD010012.

Author Information

  1. 1

    University of the Basque Country, Department of Preventive Medicine and Public Health, Leioa, Bizkaia, Spain

  2. 2

    University of the Basque Country, Department of Neuroscience, Leioa, Spain

  3. 3

    University of the Basque Country, Centre for Biomedical Research Network on Mental Health (CIBERSAM), Leioa, Spain

  4. 4

    Hospital Universitario Cruces, Molecular Genetics Laboratory, Department of Biochemistry, Barakaldo, Bizkaia, Spain

  5. 5

    Institute of Biomedical Research (IIB Sant Pau), Iberoamerican Cochrane Centre, Barcelona, Catalunya, Spain

*José-Ramón Rueda, Department of Preventive Medicine and Public Health, University of the Basque Country, GIU 10/24, UPV-EHU, Leioa, Bizkaia, E-48080, Spain. joseramon.rueda@ehu.es.

Publication History

  1. Publication Status: New
  2. Published Online: 15 AUG 2012

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To review the efficacy and safety of L-acetylcarnitine in the treatment of people with fragile X syndrome.